Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Li, Qiyan; Liu, Yulin; Huang, Zihua; Guo, Yajie; Li, Qingjiao

doi:10.3389/fbioe.2022.878524

Cited by 12 publications

(11 citation statements)

References 161 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially, the presence of abundant immune cells such as LCs, DCs, and T cells in the skin provides a great advantage for the transdermal delivery of immunotherapy for melanoma. 208 Kim et al developed immunotherapeutic testing utilizing PTET in HA MNs to deliver the cytotoxic T cell epitope peptide (SIINFEKL) with low molecular weight HA for tumors and efficiently induce antigen-specific CD8 + cytotoxic T lymphocyte (CTL) activity. 209 Hu et al developed a dendritic cell targeted immunotherapy system involving a mannose targeting functionalized (TAT:RRRQRRKKRC)-SH-PEI copolymer (CPPU-PEI1800-MAN) to load malignant melanoma Trp2 DNA as an immunotherapeutic drug.…”

Section: Applications Of Ptet In Tumor Therapymentioning

confidence: 99%

“…The tumor eradication effect was achieved at 12 days after drug administration in a tumor mouse model.Immunotherapy plays an important role in metastatic melanoma by effectively improving the survival of clinical patients. Especially, the presence of abundant immune cells such as LCs, DCs, and T cells in the skin provides a great advantage for the transdermal delivery of immunotherapy for melanoma 208. Kim et al developed immunotherapeutic testing utilizing PTET in HA MNs to deliver the cytotoxic T cell epitope peptide (SIINFEKL) with low molecular weight HA for tumors and efficiently induce antigen-specific CD8 + cytotoxic T lymphocyte (CTL) activity 209.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Research progress of physical transdermal enhancement techniques in tumor therapy

Han

Liu

et al. 2023

Chem. Commun.

View full text Add to dashboard Cite

show abstract

Section: Applications Of Ptet In Tumor Therapymentioning

confidence: 99%

mentioning

confidence: 99%

Research progress of physical transdermal enhancement techniques in tumor therapy

Han

Liu

et al. 2023

Chem. Commun.

View full text Add to dashboard Cite

show abstract

“…While viral vectors are the most often used, non‐viral vectors are quickly gaining popularity. Immunotherapy employs pharmaceuticals engineered to stimulate the body's immune system to fight cancer cells 36 . Current challenges usually involve: Immunotherapy is not without its possible side effects.…”

Section: Introductionmentioning

confidence: 99%

“…Immunotherapy employs pharmaceuticals engineered to stimulate the body's immune system to fight cancer cells. 36 Current challenges usually involve: Immunotherapy is not without its possible side effects. There are three main problems with cancer immunotherapy: Intravenous medication administration entails the accompanying potential for short-term inhibition of the malignancy response and substantial immune-related detrimental impact.…”

Section: Introductionmentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract

“…In this review, we first give a short overview on the recent advances and the current state of knowledge of ICD modalities, including apoptosis, necroptosis, ferroptosis and pyroptosis, as well as on the achievements in the application of nanoparticles, nanomaterials and nano-drug delivery carriers in this area. In particular, since the role of nanomaterials in increasing immunogenicity of apoptosis is widely described elsewhere ( 16 , 17 ), we will main focus our attention on the non-canonical cell deaths. Next, we will discuss potential mechanisms by which nanoparticle-based technology can be used to increase the immunogenicity of dying cancer cells based on the interplay between the use of nanomaterials and interference with the clearance of dying cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

et al. 2022

View full text Add to dashboard Cite

Immunogenic cell death (ICD) is a rapidly growing research area representing one of the emerging therapeutic strategies of cancer immunotherapy. ICD is an umbrella term covering several cell death modalities including apoptosis, necroptosis, ferroptosis and pyroptosis, and is the product of a balanced combination of adjuvanticity (damage-associated molecular patterns and chemokines/cytokines) and antigenicity (tumor associated antigens). Only a limited number of anti-cancer therapies are available to induce ICD in experimental cancer therapies and even much less is available for clinical use. To overcome this limitation, nanomaterials can be used to increase the immunogenicity of cancer cells killed by anti-cancer therapy, which in themselves are not necessarily immunogenic. In this review, we outline the current state of knowledge of ICD modalities and discuss achievements in using nanomaterials to increase the immunogenicity of dying cancer cells. The emerging trends in modulating the immunogenicity of dying cancer cells in experimental and translational cancer therapies and the challenges facing them are described. In conclusion, nanomaterials are expected to drive further progress in their use to increase efficacy of anti-cancer therapy based on ICD induction and in the future, it is necessary to validate these strategies in clinical settings, which will be a challenging research area.

show abstract

Triggering Immune System With Nanomaterials for Cancer Immunotherapy

Cited by 12 publications

References 161 publications

Research progress of physical transdermal enhancement techniques in tumor therapy

Research progress of physical transdermal enhancement techniques in tumor therapy

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

Contact Info

Product

Resources

About